Study identifier:D5881C00006
ClinicalTrials.gov identifier:NCT02370537
EudraCT identifier:2014-003511-11
CTIS identifier:N/A
A Two-part, Open-label, Randomised, Crossover, Multicentre, Phase II Study to Investigate the Presence of Pancreatic Exocrine Insufficiency (PEI) in Patients with Type 2 Diabetes Mellitus, and to Investigate the Pharmacokinetics of EPANOVA® and OMACOR® Following a Single Oral Dose in Patients with Different Degrees of PEI
Diabetes Mellitus, Type 2
Phase 2
No
Epanova® (omega-3 carboxylic acids), Omacor® (omega-3-acid ethyl esters)
All
490
Interventional
18 Years - 70 Years
Allocation: Randomized
Endpoint Classification: Pharmacokinetics
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Sequence AB A single dose of EPANOVA® 4 g (administered as 4 x 1 g capsules) at Visit 4, followed by 10 to 14 days washout, followed by a single dose of OMACOR® 4 g (administered as 4 x 1 g capsules) at Visit 7. | Drug: Epanova® (omega-3 carboxylic acids) 4 g (administered orally as 4 x 1 g capsules) Other Name: omega-3 carboxylic acids Drug: Omacor® (omega-3-acid ethyl esters) 4 g (administered orally as 4 x 1 g capsules) Other Name: omega-3-acid ethyl esters |
Experimental: Sequence BA A single dose of OMACOR® 4 g (administered as 4 x 1 g capsules) at Visit 4, followed by 10 to 14 days washout, followed by a single dose of EPANOVA® 4 g (administered as 4 x 1 g capsules) at Visit 7. | Drug: Epanova® (omega-3 carboxylic acids) 4 g (administered orally as 4 x 1 g capsules) Other Name: omega-3 carboxylic acids Drug: Omacor® (omega-3-acid ethyl esters) 4 g (administered orally as 4 x 1 g capsules) Other Name: omega-3-acid ethyl esters |